A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A

NCT03105349 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No availability of investigational medication.

Conditions

HCV

Interventions

DRUG: elbasvir/grazoprevir
DRUG: Sofosbuvir
DRUG: Ribavirin

Sponsor

Fundacion SEIMC-GESIDA